SC
Stempoint Capital Portfolio holdings
AUM
$311M
This Quarter Return
+23.56%
1 Year Return
+15.22%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$348M
AUM Growth
–
Cap. Flow
+$348M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
42.53%
Holding
63
New
55
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Roivant Sciences
ROIV
|
$24.4M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
$23.7M |
| 3 |
Arcellx
ACLX
|
$17.4M |
| 4 |
Merus
MRUS
|
$13.8M |
| 5 |
Immunovant
IMVT
|
$13.6M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 98.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SAGE
26
DELISTED
Sage Therapeutics
SAGE
| $4.73M | 1.26% |
+218,319
| New | +$4.73M |
|
27
Madrigal Pharmaceuticals
MDGL
$9.76B
| $4.73M | 1.26% |
+20,444
| New | +$4.73M |
|
28
SPDR S&P 500 ETF Trust
SPY
$651B
| $4.72M | 1.26% |
+9,921
| New | +$4.72M |
|
29
ANI Pharmaceuticals
ANIP
$2.04B
| $4.71M | 1.26% |
+85,382
| New | +$4.71M |
|
|
ALPN
30
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $4.69M | 1.25% |
+246,178
| New | +$4.69M |
|
31
89bio
ETNB
$1.35B
| $4.56M | 1.22% |
+408,257
| New | +$4.56M |
|
|
SLRN
32
DELISTED
ACELYRIN
SLRN
| $4.38M | 1.17% |
+587,373
| New | +$4.38M |
|
|
CBAY
33
DELISTED
Cymabay Therapeutics
CBAY
| $4.3M | 1.15% |
+182,258
| New | +$4.3M |
|
34
Olema Pharmaceuticals
OLMA
$422M
| $3.95M | 1.05% |
+281,287
| New | +$3.95M |
|
35
Larimar Therapeutics
LRMR
$323M
| $3.56M | 0.95% |
+783,172
| New | +$3.56M |
|
36
scPharmaceuticals
SCPH
$296M
| $3.56M | 0.95% |
+567,211
| New | +$3.56M |
|
37
Fate Therapeutics
FATE
$119M
| $3.36M | 0.9% |
+898,196
| New | +$3.36M |
|
38
Kiniksa Pharmaceuticals
KNSA
$2.54B
| $3.21M | 0.86% |
+183,102
| New | +$3.21M |
|
39
Applied Therapeutics
APLT
$75.9M
| $3.04M | 0.81% |
+907,152
| New | +$3.04M |
|
40
Neurocrine Biosciences
NBIX
$14.1B
| $2.96M | 0.79% |
+22,500
| New | +$2.96M |
|
|
AUTL
41
Autolus Therapeutics
AUTL
$383M
| $2.91M | 0.78% |
+451,375
| New | +$2.91M |
|
42
Annexon
ANNX
$231M
| $2.76M | 0.74% |
+607,100
| New | +$2.76M |
|
43
Fulcrum Therapeutics
FULC
$348M
| $2.54M | 0.68% |
+376,573
| New | +$2.54M |
|
44
EyePoint Pharmaceuticals
EYPT
$822M
| $2.21M | 0.59% |
+95,732
| New | +$2.21M |
|
45
AC Immune
ACIU
$222M
| $2.17M | 0.58% |
+434,588
| New | +$2.17M |
|
46
Cytokinetics
CYTK
$5.98B
| $2.01M | 0.54% |
+24,111
| New | +$2.01M |
|
47
Arrowhead Research
ARWR
$3.59B
| $1.81M | 0.48% |
+59,038
| New | +$1.81M |
|
|
AMAM
48
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $1.8M | 0.48% |
+126,101
| New | +$1.8M |
|
49
RAPT Therapeutics
RAPT
$199M
| $1.45M | 0.39% |
+58,450
| New | +$1.45M |
|
50
Ocular Therapeutix
OCUL
$2.2B
| $1.25M | 0.33% |
+279,648
| New | +$1.25M |
|